A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychot

Clinical Psychopharmacology and Neuroscience

Volumn 13, Issue 2, 2015, Pages 121-128

  Chou, Yuan Hwa ^a   Chu, Po Chung ^b,c   Wu, Szu Wei ^d   Lee, Jen Chin ^e   Lee, Yi Hsuan ^f   Sun, I Wen ^g   Chang, Chen Lin ^h   Huang, Chien Liang ⁱ   Liu, I Chao ^j   Tsai, Chia Fen ^k   Yen, Yung Chieh ^l  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d Wei Gong Memorial General Hospital   (Taiwan)

^e Ministry of Health and Welfare   (Taiwan)

^f TAINAN MUNICIPAL HOSPITAL   (Taiwan)

^g MACKAY MEMORIAL HOSPITAL   (Taiwan)

^h KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^j CARDINAL TIEN HOSPITAL   (Taiwan)

^k TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^l E DA HOSPITAL   (Taiwan)

more..

Author keywords

Bipolar disorder; Consensus; Long acting injectable antipsychotics; Risperidone

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; LAMOTRIGINE; LITHIUM; LONG ACTING DRUG; MICROSPHERE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONSENSUS; CONTROLLED CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DSM-IV; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MANIA; MEDICAL SOCIETY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; THERAPEUTIC EQUIVALENCE;

EID: 84939560557     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2015.13.2.121     Document Type: Review

References (38)

1. El-Hage W, Surguladze SA. Emerging treatments in the management of bipolar disorder-focus on risperidone long acting injection. Neuropsychiatr Dis Treat 2010;6:455-464.
2. Kemp DE, Canan F, Goldstein BI, McIntyre RS. Longacting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther 2009;26:588-599.
3. Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unützer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007;68:1237-1245.
4. Osby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-850.
5. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al; Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8:721-739.
6. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8:232-241.
7. El-Mallakh RS. Medication adherence and the use of long-acting antipsychotics in bipolar disorder. J Psychiatr Pract 2007;13:79-85.
8. Rainer MK. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat 2008;4:919-927.
9. Gutiérrez-Rojas L, Jurado D, Martínez-Ortega JM, Gurpegui M. Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Disord 2010;127:77-83.
10. Kennedy WK. When and how to use long-acting injectable antipsychotics. Current Psychiatry 2012;11:40-43.
11. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl 2009;52:S13-S19.
12. Janssen Pharmaceuticals. Risperdal Consta [package insert]. Titusville, NJ:Division of Ortho-McNeil-Janssen Pharmaceuticals Inc.;2011.
13. Gopalakrishna G, Aggarwal A, Lauriello J. Long-acting injectable aripiprazole: how might it fit in our tool box? Clin Schizophr Relat Psychoses 2013;7:87-92.
14. Otsuka Pharmaceutical Company. Abilify Maintena [package insert]. Tokyo, Japan:Otsuka Pharmaceutical Company;2013.
15. Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs 2012;26:403-420.
16. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1-50.
17. Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, et al. A randomized, double-blind, placebocontrolled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11: 827-839.
18. Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012;22:825-835.
19. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl 2007;(434):50-56.
20. Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol 2006;26:530-531.
21. Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1219-1223.
22. Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int Clin Psychopharmacol 2008;23: 88-94.
23. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68:156-162.
24. Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry 2011;11:171.
25. Bobo WV, Shelton RC. Risperidone long-acting injectable (Risperdal Consta) for maintenance treatment in patients with bipolar disorder. Expert Rev Neurother 2010;10:1637-1658.
26. Gray R, Spilling R, Burgess D, Newey T. Antipsychotic long-acting injections in clinical practice: medication management and patient choice. Br J Psychiatry Suppl 2009;52:S51-S56.
27. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381:1672-1682.
28. El-Mallakh RS, Elmaadawi AZ, Gao Y, Lohano K, Roberts RJ. Current and emerging therapies for the management of bipolar disorders. J Cent Nerv Syst Dis 2011;3:189-197.
29. Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013;13:340.
30. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44.
31. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-388.
32. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14:154-219.
33. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85-116.
34. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al; WFSBP Task Force On Treatment Guidelines For Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11:81-109.
35. National Collaborating Centre for Mental Health (UK). Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Leicester, UK:British Psychological Society;2006.
36. Crismon ML, Argo TR, Bendele SD, Suppes T. Texas medication algorithm project procedural manual: bipolar disorder algorithms. Austin:Texas Department of State Health Services;2007.
37. Bai YM, Chang CJ, Tsai SY, Chen YC, Hsiao MC, Li CT, et al. Taiwan consensus of pharmacological treatment for bipolar disorder. J Chin Med Assoc 2013;76:547-556.
38. Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull 2013;39:993-998.